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Background. Inflammatory bowel disease results from the dysregulation of immune response to environmental and microbial
agents in genetically susceptible individuals. The aim of the present study was to examine the effect of rifaximin and/or Mutaflor
(Escherichia coliNissle 1917, EcN) administration on the healing of acetic acid-induced colitis.Methods. Colitis was induced inmale
Wistar rats by rectal enema with 3.5% acetic acid solution. Rifaximin (50mg/kg/dose) and/or Mutaflor (109 CFU/dose) were given
intragastrically once a day. The severity of colitis was assessed at the 8th day after induction of inflammation. Results. Treatment
with rifaximin significantly accelerated the healing of colonic damage. This effect was associated with significant reversion of the
acetic acid-evoked decrease inmucosal blood flow andDNA synthesis. Moreover, administration of rifaximin significantly reduced
concentration of proinflammatory TNF-𝛼 and activity of myeloperoxidase in colonic mucosa. Mutaflor given alone was without
significant effect on activity of colitis. In contrast, Mutaflor given in combination with rifaximin significantly enhanced therapeutic
effect of rifaximin. Moreover, Mutaflor led to settle of the colon by EcN and this effect was augmented by pretreatment with
rifaximin. Conclusion. Rifaximin and Mutaflor exhibit synergic anti-inflammatory and therapeutic effect in acetic acid-induced
colitis in rats.
1. Introduction
Genetic and environmental factors are involved in pathogen-
esis of inflammatory bowel disease (IBD). IBD results from
the dysregulation of immune response to environmental
and microbial agents in genetically susceptible individuals
[1, 2]. Intestinal microflora plays a role in promoting and
maintaining inflammatory process in this disease [3]. The
intestinal flora contains various pathogens such as Clostrid-
ium perfringens, Enterococcus, Enterobacteriaceae, and Bac-
teroides. These bacteria are present in the large intestine
of every healthy person in high concentrations, but, in the
normal condition, they are separated from the colonic wall
by an impenetrable mucus layer and are tolerated by the
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host. In patients with IBD, this separation is disturbed;
bacteria adhere to the mucosa and invade epithelial cells
with concomitant inflammatory response [4]. Moreover, the
concentration of mucosal bacteria is higher in patients with
IBD than in healthy persons and this concentration is
proportional to the severity of the disease [4, 5].
Rifaximin is a locally acting antibacterial agent that is
practically unabsorbed after oral administration (absorption
less than 0.4%) and for this reason this medicine is risk-free
of systemic side effects. Rifaximin exhibits a broad-spectrum
activity against enteric Gram-positive and Gram-negative
bacteria. Rifaximin has been found to be useful in the
treatment of traveler’s diarrhea and irritable bowel syndrome
and in preventing of the stress-induced gut inflammation
[6–9]. There are studies showing that rifaximin is effective
in the treatment of IBD. Clinical trials have indicated that
administration of 800mg rifaximin twice daily for 12 weeks
induces remission with few adverse events in patients with
moderately active Crohn’s disease (CD) [10], and remission
previously obtainedwith standard treatment can be sustained
in patients with moderately active CD by administration of
rifaximin as well [11]. Rifaximin has been also found to be
effective in the treatment of ulcerative colitis [12–14].
Living microorganisms that enter gastrointestinal tract
and exert a beneficial effect on the host are called probiotics.
There are studies showing the therapeutic effect of probiotics
in the prevention or treatment of the gastrointestinal tract
diseases [15, 16].
Escherichia coli Nissle 1917 (EcN) is a nonpathogenic
strain of the Enterobacteriaceae family. It was originally
isolated by a physician Alfred Nissle during the First World
War on the Balkan Peninsula from the feces of a soldier, who
in contrast to his comrades, did not develop enterocolitis
[17]. Study performed by Altenhoefer et al. [18] has tested
the interference of EcN with Salmonella invasion of human
embryonic intestinal epithelial INT407 cells. Simultaneous
administration of EcN 1917 and Salmonella enterica serovar
Typhimurium strain C17 resulted in up to 70% reduction
of Salmonella invasion efficiency. Furthermore, invasion
of Yersinia enterocolitica, Shigella flexneri, Legionella pneu-
mophila, and even Listeria monocytogenes was inhibited by
EcN without affecting the viability of the invasive bacteria.
There are also studies indicating the therapeutic effect of the
EcN in patientswith IBD.Maintaining remission in ulcerative
colitis by the treatment with EcN has been shown to be as
effective as treatment with “the gold standard” mesalazine
[19–22]. On the other hand, there is only one clinical study
showing beneficial effect of EcN in maintaining remission in
patients with colonic Crohn’s disease [23]. Application of EcN
has reduced the risk for relapse and minimized the need for
glucocorticoids.
The above observations suggest that rifaximin and
Mutaflor can influence the course of IBD. The aim of the
present study was to compare the effect of treatment with
rifaximin and Mutaflor on the healing of acetic acid-induced
colitis in rats. In addition, we investigated whether adminis-
tration of the combination of rifaximin plus Mutaflor leads
to any synergic interaction of their therapeutic effects in this
model of IBD.
2. Materials and Methods
2.1. Animals and Treatment. Studies were performed on 64
male Wistar rats weighing 250–270 g and were conducted
following the experimental protocol approved by the First
Local Commission of Ethics for the Care and Use of Labo-
ratory Animals in Cracow (Permit Number 2/2013 released
on January 16, 2013). Animals were housed in cages in room
temperature and a 12 h light-dark cycle. Rats were fasted with
free access to water for 18 h before induction of colitis. Later
food and tap water were available ad libitum.
Animals were randomly divided into eight equal exper-
imental groups: (1) control rats without induction of colitis
and treated intragastrically (i.g.) with saline; (2) rats without
induction of colitis and treated i.g. with Escherichia coliNissle
1917 (EcN); (3) rats without induction of colitis and treated
i.g. with rifaximin; (4) rats without induction of colitis and
treated i.g. with the combination of rifaximin plus EcN; (5)
rats treated i.g. with saline after induction of colitis; (6) rats
treated i.g. with EcN after induction of colitis; (7) rats treated
i.g. with rifaximin after induction of colitis; and (8) rats
treated i.g. with the combination of rifaximin plus EcN after
induction of colitis.
Colitis was induced by a rectal enema with 1mL of
3.5% (v/v) acetic acid aqueous solution in rats anesthetized
with ketamine (50mg/kg i.p., Bioketan, Vetoquinol Biowet,
Gorzów Wielkopolski, Poland). Acetic acid solution was
administered through a polyethylene catheter inserted into
the rectum.There are different models of acetic acid-induced
colitis and the tip of catheter can be positioned from
1.2 [24] to 8 cm [25] proximal to the anus verge. For this
reason we have chosen an intermediate depth of catheter
insertion, 4.5 cm from the anus. Rats without induction of
colitis obtained rectal enema with an aqueous saline solution
administered in the same manner as a solution of acetic acid
in animals with induction of colitis.
Rifaximin (50mg/kg/dose; Xifaxan, Norgine B.V., Am-
sterdam, Netherlands) and/or the probiotic strain Escheri-
chia coli Nissle 1917 (approx. 109 CFU/dose, Mutaflor; Ar-
deypharm GmbH, Herdecke, Germany) were given i.g. once
a day for 7 days, starting at the day of colitis induction.
Each dose of Mutaflor was given 2 h after treatment with
rifaximin. In rats treated with saline, each dose of saline was
given at the same time as in animals treated with Mutaflor.
The last administration of saline, rifaximin, Mutaflor, or the
combination of rifaximin plus Mutaflor was carried out 24 h
before the end of experiment.
At the 8th day of study, animals were anesthetized and
the research was terminated. This single observation period
was chosen because the protocol of our research has been
prepared in accordance with the policy of 3Rs (Replacement,
Reduction and Refinement). Previous studies have shown
that the potential therapeutic effects of factors being tested
are clearly visible on the 8th day of study after the seven-day
treatment [26].
2.2. Measurement of Colonic Blood Flow and Colonic Damage.
Seven days after rectal enema with saline or induction of
colitis, rats were anesthetized again with ketamine. After
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opening the abdominal cavity and exposure of the colon,
the rate of colonic blood flow was measured using laser
Doppler flowmeter (PeriFlux 4001 Master monitor, Perimed
AB, Järfälla, Sweden), as described previously [27]. The mea-
surement of mucosal blood flowwas performed every time in
five parts of the descending and sigmoid colon and the main
value of five records was expressed as the percentage of the
value obtained in the animals from the control group. After
the measurement of colonic blood flow, anesthetized animals
were euthanized by exsanguination from the abdominal
aorta.Then, the area ofmucosal damage wasmeasured, using
a computerized planimeter (Morphomat, Carl Zeiss, Berlin,
Germany), as described previously [28].
2.3. Biochemical Analysis. After measurement of the area of
mucosal damage, biopsy samples of colonic wall or colonic
mucosa were taken for histological examination and deter-
mination of mucosal DNA synthesis (an index of mucosal
cell vitality and proliferation), mucosal interleukin-1𝛽 (IL-
1𝛽) and Tumor Necrosis Factor-𝛼 (TNF-𝛼) concentration,
and mucosal activity of myeloperoxidase. DNA synthesis
was determined by measurement of [3H]thymidine incor-
poration ([6-3H]-thymidine, 20–30Ci/mmol, Institute for
Research, Production and Application of Radioisotopes,
Prague, Czech Republic) into mucosal DNA as described
previously [29]. The incorporation of labeled thymidine into
DNA was determined by counting 0.5mL DNA-containing
supernatant in a liquid scintillation system. DNA synthesis
was expressed as tritium disintegrations per minute per
microgram of DNA (dpm/𝜇g DNA).
Samples of the colonic mucosa, in which the concentra-
tion of IL-1𝛽 and TNF-𝛼 was measured, were homogenized
in phosphate buffer at 4∘C. Then the homogenate was
centrifuged and the concentration of IL-1𝛽 and TNF-𝛼 was
determined in the supernatant using the Rat IL-1𝛽 Platinum
ELISA (Bender MedSystem GmbH, Vienna, Austria) or Rat
TNF-𝛼 ELISA Kit (Koma Biotech, Seoul, South Korea),
respectively. The concentration of IL-1𝛽 and TNF-𝛼 in the
colonic mucosa was expressed in nanograms per 1 gram of
tissue.
Biopsy samples for measurement of mucosal myeloper-
oxidase activity were homogenized in ice-cold potassium
phosphate and, until the marking was done, stored at the
temperature of−60∘C.Markingmyeloperoxidase activity was
performed with the use of a modification of the method
described by Bradley et al. [30]. Results were expressed in
units per gram of tissue.
2.4. Histological Examination of the Colon. Samples of the
colon were fixed in 10% buffered formaldehyde and embed-
ded in paraffin. Paraffin sections were stained with hema-
toxylin and eosin and examined by the pathologist unin-
formed about treatment given. The histological grading of
colonic damage such as ulceration, inflammation, depth of
the lesion, and fibrosis was determined using a scale of
Vilaseca et al. [31] as described in detail previously [32].
2.5. Microbiological Analysis. Feces samples were taken and
transported in deep-freeze conditions to the microbiological
laboratory where DNA was extracted according to the previ-
ously described procedure [33].
Escherichia coli and Enterococcus species in the fecal sam-
ples were quantified by quantitative real time PCR (qPCR)
according to the method described by Pilarczyk-Zurek et
al. [34] and Ryu et al. [35], respectively. To detect specific
DNA sequences, ready-to-use JumpStart Taq ReadyMix kit
(Sigma-Aldrich, Saint Louis, USA), fluorescently FAM dye
labeled probe (F) GGGAGTAAAGTTAATACCTTTGC, (R)
CTCAAGCTTGCCAGTATCAG,FAM-CGCGATCACTCC-
GTGCCAGCAGCCGCGGATCGCG-BHQ1 (GenoMed) for
E. coli, and (ECST748F) AGAAATTCCAAACGAACTTG
and (ENC854R) CAGTGCTCTACCTCCATCATT for Ente-
rococcus spp. (SYBR Green dye) were used. A standard
curve was prepared. DNA from given numbers of E. coli
ATCC25922 and separately E. faecalisATCC19433 was added
in serial dilutions from 101 to 107 cells to a series of qPCRs.
The reactions were carried out in a CFX96 thermocycler
(BioRad). Detection and quantitation were linear over the
range of DNA concentrations examined. To determine the
number of both bacterial species cells, the fluorescent signals
detected from DNA feces samples (in duplicate) in the linear
range of the assay were averaged and compared to a standard
curve.
EcN DNA in the fecal samples were detected by triplex
PCR method described by Blum-Oehler et al. [36] using
three primers pairs: Muta 5/6; Muta 7/8; and Muta 9/10.
The reactions were carried out on the CFX96 thermocycler
(BioRad). All PCR products were analyzed by electrophoresis
through 3% agarose gels (Prona).
2.6. Statistical Analysis. Statistical analysis of the data was
carried out by one-way analysis of variance (ANOVA) fol-
lowed by Tukey’s multiple comparison test using GraphPad
Prism (GraphPad Software, San Diego, CA, USA). Differ-
ences were considered to be statistically significant when 𝑃
was less than 0.05.
3. Results
Macroscopic andmicroscopic evaluation of the colon showed
no damage in control saline-treated animals without induc-
tion of colitis (Figure 1, Table 1, and Figure 2(a)). No colonic
damage was also seen in animals without induction of
colitis and treated withMutaflor, rifaximin, or a combination
thereof (Figure 1, Table 1). Rectal enema with acetic acid
solution caused induction of colitis in all rats subjected
to this procedure. In saline-treated rats, 7 days after the
induction of colitis, the area of mucosal damage reached a
value of 11.5 ± 0.6mm2. Microscopic examination of the
colon showed the presence of large lesions reaching the level
of muscular membrane or even serous membrane (Table 1,
Figure 2(b)). This alteration was associated with moderate
or heavy inflammatory infiltration and the presence of mild
fibrosis.
Macroscopic examination showed that treatment with
Mutaflor given alone after induction of colitis tended to
reduce the area of mucosal damage in the colon; however this
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Figure 1: Influence of E. coli Nissle 1917 (Mutaflor) and rifaximin on the area of colonic lesions in rats without or with acetic acid-induced
colitis. Mean value ± SEM.𝑁 = 8 animals in each experimental group. a𝑃 < 0.05 compared to control saline-treated rats without induction
of colitis; b𝑃 < 0.05 compared to colitis + NaCl; c𝑃 < 0.05 compared to colitis + Mutaflor; and d𝑃 < 0.05 compared to colitis + rifaximin.
Table 1: Influence of Escherichia coli Nissle 1917 (Mutaflor) and rifaximin on morphological signs of colonic damage in rats without or with
acetic acid-induced colitis observed 8 days after rectal administration of saline or acetic acid solution (colitis).
Morphological changes
Grading of colonic damage (0–2) Inflammatory infiltration (0–3) Depth of damage (0–3) Fibrosis (0–3)
Saline (control) 0 0 0 0
Mutaflor 0 0 0 0
Rifaximin 0 0 0 0
Rifaximin + Mutaflor 0 0 0 0
Colitis + NaCl 3 2-3 2 1-2
Colitis + Mutaflor 3 2-3 1-2 1
Colitis + rifaximin 2-3 1-2 1-2 1
Colitis + rifaximin + Mutaflor 2 1 1 0-1
Numbers represent the predominant histological grading in each group.
effect was statistically insignificant.Microscopic examination
of the colon showed no effect ofMutaflor given alone on a size
of damage and inflammatory infiltration in rats with colitis.
Only a depth of colonic damage and a grade of fibrosis were
slightly reduced in some animals (Table 1, Figure 2(c)).
In contrast, treatment with rifaximin given alone sig-
nificantly reduced the area of mucosal damage by 22%
when compared to animals with colitis treated with saline
(Figure 1). Microscopic examination showed that the admin-
istration of rifaximin reduces the extent of colonic dam-
age, inflammatory infiltration, and development of fibrosis
(Table 1, Figure 2(d)).
Maximal reduction of the area of mucosal damage in
macroscopic examination was observed in rats with colitis
treated with the combination of rifaximin plus Mutaflor.
The area of damage in those group of rats was significantly
lower than in animals treated with saline, rifaximin, or
Mutaflor given alone (Figure 1). Also microscopic evaluation
showed that treatmentwith the combination of rifaximin plus
Mutaflor maximally reduced the colonic damage in rats with
colitis (Table 1, Figure 2(e)).
In the rats without induction of colitis, administration
of Mutaflor and rifaximin given alone or in their com-
bination failed to affect mucosal blood flow in the colon
(Figure 3). Induction of colitis significantly reduced blood
flow in colonic mucosa by around 35% in comparison to
a value observed in control saline-treated rats. In rats with
colitis, administration of Mutaflor given alone tended to
improve colonic blood flow, but this effect was statistically
insignificant. In contrast, the administration of rifaximin sig-
nificantly improved blood flow through the colonic mucosa.
The greatest improvement in blood flow in colonic mucosa
of rats with colitis was observed after treatment with the
combination of rifaximin plus Mutaflor (Figure 3).
In rats without induction of colitis, administration of
Mutaflor or rifaximin given alone or in their combination
was without any effect on DNA synthesis in colonic mucosa
(Figure 4). Induction of colitis by the enema with acetic acid
led to reduction in DNA synthesis in colonic mucosa by 38%.
Administration of Mutaflor or rifaximin given alone did not
significantly affect DNA synthesis in colonic mucosa in rats
with colitis. Treatmentwith the combination of rifaximin plus
Mutaflor partly, but significantly reversed the colitis-evoked
reduction in mucosal DNA synthesis in the colon (Figure 4).
In rats without induction of colitis, intragastric admin-
istration of Mutaflor or rifaximin for 7 days failed to affect
mucosal concentration of interleukin-1𝛽 (IL-1𝛽) or Tumor
Necrosis Factor-𝛼 (TNF-𝛼) in the colon (Figures 5 and 6,
resp.). Induction of colitis caused more than 8-fold increase
in concentration of IL-1𝛽 and more than 6-fold increase in
concentration of TNF-𝛼 in colonic mucosa. Administration
of Mutaflor after induction of colitis was without significant
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Figure 2: Histological features of the rat colonic mucosa stained by haematoxylin and eosin (original magnification 400x). (a) Control rats
without induction of colitis and treated with saline for 7 days; (b) rats with colitis treated with saline for 7 days; (c) rats with colitis treated with
Mutaflor for 7 days; (d) rats with colitis treated with rifaximin for 7 days; and (e) rats with colitis treated with the combination of rifaximin
plus Mutaflor for 7 days.
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Figure 3: Influence of E. coli Nissle 1917 (Mutaflor) and rifaximin on mucosal blood flow in the colon in rats without or with acetic acid-
induced colitis. Mean value ± SEM. 𝑁 = 8 animals in each experimental group. a𝑃 < 0.05 compared to control saline-treated rats without
induction of colitis; b𝑃 < 0.05 compared to colitis + NaCl; and c𝑃 < 0.05 compared to colitis + Mutaflor.
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Figure 4: Influence of E. coli Nissle 1917 (Mutaflor) and rifaximin on DNA synthesis in colonic mucosa in rats without or with acetic acid-
induced colitis. Mean value ± SEM. 𝑁 = 8 animals in each experimental group. a𝑃 < 0.05 compared to control saline-treated rats without
induction of colitis; b𝑃 < 0.05 compared to colitis + NaCl.
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Figure 5: Influence of E. coli Nissle 1917 (Mutaflor) and rifaximin on of interleukin-1𝛽 concentration in colonic mucosa in rats without or
with acetic acid-induced colitis. Mean value ± SEM.𝑁 = 8 animals in each experimental group. a𝑃 < 0.05 compared to control saline-treated
rats without induction of colitis; b𝑃 < 0.05 compared to colitis + NaCl; c𝑃 < 0.05 compared to colitis + Mutaflor; and d𝑃 < 0.05 compared to
colitis + rifaximin.
effect on mucosal concentration of IL-1𝛽 or TNF-𝛼 in
the colon. Rifaximin administered alone caused a partial
decrease in the level of IL-1𝛽 and TNF-𝛼 in colonic mucosa
of animals with colitis. However, only the reduction of TNF-𝛼
concentration was statistically significant when compared to
level observed in rats with colitis treated with saline.Maximal
reduction in concentration of IL-1𝛽 and TNF-𝛼 in colonic
mucosa was observed after administration of combination of
rifaximin plus Mutaflor (Figures 5 and 6).
Administration of Mutaflor or rifaximin given alone as
well as treatment with the combination of rifaximin plus
Mutaflor was without any significant effect on mucosal
myeloperoxidase activity in the colon in the rats without
colitis induction (Figure 7). Induction of colitis caused more
than a 3-fold increase in myeloperoxidase activity in colonic
mucosa. Treatment with Mutaflor tended to reduce the
colitis-evoked increase in myeloperoxidase activity in the
colonic mucosa, but this effect was statistically insignificant.
In contrast, administration of rifaximin resulted in a signif-
icant reduction in mucosal activity of myeloperoxidase in
rats with colitis. Maximal reduction of the colitis-induced
increase in mucosal myeloperoxidase activity as observed
after treatment with combination of rifaximin and Mutaflor
(Figure 7).
Table 2: Influence of treatment with Escherichia coli Nissle 1917
(Mutaflor) and/or rifaximin and induction of colitis on the total
number of Escherichia coli identified by qPCR in feces samples.
Experimental groups The number of bacteria (CFU/g)
Control 2.41× 105 ± 7.59× 104
Mutaflor 6.42× 106 ± 3.21× 106
Rifaximin 2.95× 102 ± 1.69× 102
Rifaximin + Mutaflor 5.54× 104 ± 2.28× 104
Colitis + NaCl 7.57× 108 ± 4.38× 108a
Colitis + Mutaflor 1.11× 107 ± 4.22× 106b
Colitis + rifaximin 1.27× 103 ± 6.68× 102b
Colitis + rifaximin + Mutaflor 4.52× 105 ± 1.68× 105b
Mean value ± SEM. 𝑁 = 8 observations in each experimental group. a𝑃 <
0.05 compared to control; b𝑃 < 0.05 compared to colitis + NaCl.
In control rats without induction of colitis and treated i.g.
with saline, the concentration of E. coli was 2.41 × 105 colony
forming units (CFU) per gram of feces (Table 2). In rats
without induction of colitis, treatment with Mutaflor tended
to increase the concentration of E. coli in feces, whereas
administration of rifaximin tended to reduce the number of
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Figure 6: Influence of E. coli Nissle 1917 (Mutaflor) and rifaximin on of Tumor Necrosis Factor-𝛼 concentration in colonic mucosa in rats
without or with acetic acid-induced colitis. Mean value ± SEM.𝑁 = 8 animals in each experimental group. a𝑃 < 0.05 compared to control
saline-treated rats without induction of colitis; b𝑃 < 0.05 compared to colitis + NaCl; c𝑃 < 0.05 compared to colitis +Mutaflor; and d𝑃 < 0.05
compared to colitis + rifaximin.
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Figure 7: Influence of E. coli Nissle 1917 (Mutaflor) and rifaximin on myeloperoxidase activity in colonic mucosa in rats without or with
acetic acid-induced colitis. Mean value ± SEM.𝑁 = 8 animals in each experimental group and each time of observation. a𝑃 < 0.05 compared
to control saline-treated rats without induction of colitis; b𝑃 < 0.05 compared to colitis + NaCl; c𝑃 < 0.05 compared to colitis + Mutaflor;
and d𝑃 < 0.05 compared to colitis + rifaximin.
those bacteria in the stool. However, both of those results
were statistically insignificant. Induction of colitis caused
statistically significant increase in concentration of E. coli in
the stool. This effect of colitis on the number of E. coli in
feces was significantly reversed by treatment with Mutaflor
and rifaximin given alone or in their combination (Table 2).
In rats without induction of colitis and treated with
saline, the concentration of Enterococcus spp. was 3.54 × 107
colony forming units (CFU) per gram of feces (Table 3). In
rats without induction of colitis, treatment with Mutaflor or
rifaximin given alone or in their combination significantly
reduced the concentration of E. spp. in feces. Induction of
colitis significantly increased the concentration of E. spp. in
the stool. Treatment with Mutaflor and rifaximin given alone
or in their combination significantly reversed the colitis-
evoked increase in the number of E. spp. in feces (Table 3).
In all rats without treatment with Mutaflor, the presence
of E. coli Nissle 1917 (EcN) was not detected (Figure 8).
Administration of Mutaflor resulted in colonization of the
large intestine by EcN in all rats without induction of
colitis. This effect was increased in animals pretreated with
Table 3: Influence of Mutaflor (Escherichia coli Nissle 1917), rifax-
imin, and colitis applied alone or in their combination on the
number of Enterococcus spp. identified by qPCR in feces samples.
Experimental groups The number of bacteria (CFU/g)
Control 3.54× 107 ± 5.90× 104
Mutaflor 3.23× 105 ± 5.73× 103a
Rifaximin 6.88× 101 ± 3.78× 101a
Rifaximin + Mutaflor 3.59× 102 ± 7.69× 101a
Colitis + NaCl 4.34× 108 ± 5.68× 106a
Colitis + Mutaflor 2.45× 107 ± 3.22× 105a,b
Colitis + rifaximin 1.45× 102 ± 7.26× 101a,b,c
Colitis + rifaximin + Mutaflor 6.34× 104 ± 7.05× 103a,b,c
Mean value ± SEM. 𝑁 = 8 observations in each experimental group. a𝑃 <
0.05 compared to control; b𝑃 < 0.05 compared to colitis + NaCl; and c𝑃 <
0.05 compared to colitis + Mutaflor.
rifaximin before Mutaflor administration. In animals with
colitis, the colonization of the large intestine by EcN following
administration of Mutaflor was less effective. Administration
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Figure 8: Determination ofMuta 5/6 (361 bp),Muta 7/8 (427 bp), andMuta 9/10 (313 bp) amplicons by PCRmethod as indices of the presence
of E. coli Nissle 1917 (EcN). Representative findings in (line 1) control rats without induction of colitis and treated intragastrically (i.g.) with
saline; (line 2) rats without induction of colitis and treated i.g. with Mutaflor; (line 3) rats without induction of colitis and treated i.g. with
rifaximin; (line 4) rats without induction of colitis and treated i.g. with the combination of rifaximin plus Mutaflor; (line 5) rats treated i.g.
with saline after induction of colitis; (line 6) rats treated i.g. with Mutaflor after induction of colitis; (line 7) rats treated i.g. with rifaximin
after induction of colitis; and (line 8) rats treated i.g. with the combination of rifaximin plusMutaflor after induction of colitis. LineM—DNA
mass ruler.
of Mutaflor given alone in rats with colitis led to the presence
of primers specific to the EcN only in two cases on 8
observations. The addition of rifaximin before each dose of
Mutaflor improved colonization of the colon by EcN. The
presence of the EcN was observed in all animals in this
experimental group (Figure 8).
4. Discussion
Our present study has shown that treatment with rifaximin
accelerates the healing of acetic acid-induced colitis. This
effect has been found as a faster reduction in the area of
colonic damage, as well as a decrease in mucosal level of
myeloperoxidase (MPO), interleukin-1𝛽 (IL-1𝛽), and Tumor
Necrosis Factor-𝛼 (TNF-𝛼).
MPO is an enzyme most abundantly present in azuro-
philic granules of neutrophil granulocytes. Antimicrobial
function of neutrophils is related, among others, to activity
of MPO and possibility to generate hypochlorous acids and
reactive oxygen species (ROS) during the respiratory burst
[37]. MPO is released by activated neutrophils and for this
reason tissue activity of MPO reflects the degree of tissue
infiltration by neutrophils and may be used as an indirect
marker of tissue oxidative stress [37, 38]. In turn, IL-1𝛽 and
TNF-𝛼 are important proinflammatory cytokines. IL-1𝛽
is a proinflammatory cytokine responsible for initiating
the release of a cascade of proinflammatory factors during
inflammation [39]. Administration of rifaximin after induc-
tion of colitis has decreased the activity of MPO and reduced
concentration of IL-1𝛽 and TNF-𝛼 in colonic mucosa,
reflecting the reduction in the local inflammatory reaction.
Treatment with rifaximin has also affected blood flow
and DNA synthesis in colonic mucosa in rats with acetic
acid-induced colitis. Induction of colitis has strongly reduced
those parameters, whereas administration of rifaximin has
significantly improved blood flow and DNA synthesis in rats
with colitis. Mucosal blood flow plays an important role in
the protection and healing of mucosa in the gut [40, 41].
Previous studies have shown that exposure of gastric mucosa
to potentially noxious factors results in little or no damage, as
long as adequate blood flow ismaintained, whereas reduction
in mucosal blood flow leads to severe gastric injury [41].
Rate of mucosal DNA synthesis can be recognized as an
index of cell vitality and cell proliferation. Previous studies
have shown that inhibition of mucosal cell proliferation
or excessive apoptosis results in the development of ulcers
[42, 43], whereas a stimulation of mucosal cell proliferation
exhibits protective and healing in the gastrointestinal tract
[28, 44–46].
Therapeutic effect of rifaximin in acetic acid-induced col-
itis shown in our present study is in harmony with previous
experimental [47] and clinical studies [10–13].
In contrast to effects obtained after treatment with rifax-
imin, we have found that administration of Mutaflor tends
to improve the healing of acetic acid-induced colitis, but this
effect is weak and statistically insignificant. Moreover, the
presence of Escherichia coli strain Nissle 1917 (EcN) has been
found only in feces of two per eight rats treated withMutaflor
alone after induction of colitis. This observation explains
why studies showing the therapeutic effect of EcN in colitis
are so few and far between. There are some experimental
studies performed on rodents showing preventive and/or
therapeutic effect of pretreatment or treatment with EcN in
colitis evoked by dextran sodium sulfate [48], trinitrobenzene
sulfonic acid [49], or transfer of CD4+ CD62L+ T lym-
phocytes from BALB/c mice in SCID mice [48]. Moreover,
there are three clinical studies performed in adult patients
[19–21] and one in children and adolescents [50] showing
that EcN (Mutaflor) given orally is useful in preventing
relapses in inactive ulcerative colitis (UC) and its efficacy is
comparable to effects of standard therapy with mesalazine.
Moreover, studies performed by Rembacken et al. [21] have
found that oral treatment with EcN leads to remission in the
similar percentage of patients with active ulcerative colitis
as treatment with mesalazine. Unfortunately, their data are
difficult to interpret because all patients at the same timewere
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treated with hydrocortisone acetate enemas or prednisone
given orally according to the severity of disease. Moreover,
all patients received a 1-week course of oral gentamicin [21].
There is also clinical trial examining the potential thera-
peutic effect EcN in UC [22]. Patients with moderate distal
activity in UC were assigned to treatment with either 40, 20,
or 10mL enemas containing 108 EcN/mL or placebo. Authors
have found that according to an intent-to-treat-population
analysis the number of responders was not significantly
higher in EcN group than in the placebo group. On the other
hand, they have also reported that the Jonckheere-Terpstra
rank correlation for dose-dependent efficiency indicated a
significant correlation of per-protocol responder rates. Time
to remission was shortest in patients treated with EcN 40mL.
However, it must be pointed out that groups of patient were
not equivalent.
In the case of Crohn’s disease (CD), there is only one
clinical study showing that administration of EcN can help
in maintaining remission in this disease [23].
The most important finding of our present study is the
observation that administration of combination of rifaximin
plus EcN in the course of acetic acid-induced colitis generates
a greater therapeutic effect than any of these agents given
alone. It was manifested by a statistically significant acceler-
ation of healing of colonic damage, as well as by a reduction
in local inflammatory process found as a decrease in MPO
activity and a reduction in concentration of IL-1𝛽 and TNF-𝛼
in colonic mucosa. Moreover, we have found that treatment
with combination of rifaximin plus EcNmaximally improves
blood flow and DNA synthesis in mucosa of the colon in rats
with colitis.
Another important finding of our present study was the
observation that pretreatment with rifaximin before admin-
istration of EcN favors the colonization of the colon by EcN.
The presence of EcN has been found in all rats treated with
the combination of rifaximin plus Mutaflor. Currently, great
attention is given to the role of commensal bacteria in the
pathogenesis of IBD. There are studies showing an increase
in colonic population of Enterobacteriaceae, including E. coli
in patients with UC and CD versus a control group [51].
Kleessen et al. [51] have found a bacterial invasion of mucosa
in colonic specimens of UC patients, as well as in ileal and
colonic specimens obtained from CD patients. In contrast to
that, no bacteria were detected in tissues of healthy humans
[51]. Similar findings have been found byMylonaki et al. [52].
They have detected higher number of epithelium-associated
E. coli in active than inactive UC or controls. Epithelium-
associated E. coli counts were also higher in CD. Moreover
E. coli were also found as individual bacteria and in clusters
in the lamina propria in UC and CD patients but in none of
the controls.
In harmony with the above-mentioned observations are
recent studies performed by Elliott et al. [53] and Vazeille et
al. [54]. Elliott et al. [53] have found that intramacrophage E.
coli are commonly observed in lamina propria macrophages
in mucosal biopsies from CD patients, rarely in UC and
not at all in healthy controls. Authors have concluded that
persistence of E. coli within macrophages located in lamina
propria may provide a stimulus for chronic inflammation.
The role of E. coli in the pathogenesis of IBD has also been
confirmed by findings of Vazeille et al. [54]. They have found
that monocyte-derived macrophages from CD patients are
impaired in the ability to control intracellular adherent-
invasive E. coli and exhibit disordered cytokine profile.
Moreover, currently performed meta-analysis has revealed
that intestinal colonizationwith phylogenetic group B2 E. coli
is associated with UC [55].
Data mentioned above and our results taken together
suggest that substitution of other, potentially pathogenic
strains of E. coli by nonpathogenic strain Nissle 1917 plays
an important role in therapeutic effect of coadministration
of rifaximin plus Mutaflor in acetic acid-induced colitis.
Substitution of other E. coli strains by EcN is also important
due to the rapid development of resistance of E. coli against
rifaximin in the case of use of this antibiotic [56]. Moreover,
our present study has shown treatment with Mutaflor and
rifaximin given alone or in their combination significantly
reversed the colitis-evoked increase in the colonic number of
Enterococcus spp.
Finally, we conclude that rifaximin and Mutaflor exhibit
synergic anti-inflammatory and therapeutic effect in acetic
acid-induced colitis in rats. This observation suggests that
rifaximin plus Mutaflor may be the optimal choice in the
treatment of colitis by probiotics.
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[15] S. K. Böhm and W. Kruis, “Probiotics: do they help to control
intestinal inflammation?” Annals of the New York Academy of
Sciences, vol. 1072, pp. 339–350, 2006.
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